Ningbo MedicalSystem Biotechnology Co Ltd (300439) - Total Liabilities
Based on the latest financial reports, Ningbo MedicalSystem Biotechnology Co Ltd (300439) has total liabilities worth CN¥706.76 Million CNY (≈ $103.42 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Ningbo MedicalSystem Biotechnology Co Lt strategic investment ratio to see how much of total assets are deployed in long-term investments.
Ningbo MedicalSystem Biotechnology Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Ningbo MedicalSystem Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Ningbo MedicalSystem Biotechnology Co Lt.
Ningbo MedicalSystem Biotechnology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Ningbo MedicalSystem Biotechnology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hunan Chen Dian International Development Co Ltd
SHG:600969
|
China | CN¥10.00 Billion |
|
Sichuan Expressway Company Limited
F:EXF1
|
Germany | €42.46 Billion |
|
WINBO-Dongjian Automotive Technology Co. Ltd.
SHE:300978
|
China | CN¥836.85 Million |
|
Shenzhen Sosen Electronics Co.Ltd.
SHE:301002
|
China | CN¥662.61 Million |
|
Globalworth REIT
LSE:GWI
|
UK | €1.46 Billion |
|
Beijing Haohan Data Technology Co. Ltd. A
SHG:688292
|
China | CN¥474.86 Million |
|
Aurelia Metals Ltd
AU:AMI
|
Australia | AU$184.83 Million |
|
ZJBC Information Technology Co Ltd
SHE:000889
|
China | CN¥885.66 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Ningbo MedicalSystem Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 300439 net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ningbo MedicalSystem Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ningbo MedicalSystem Biotechnology Co Ltd (2011–2024)
The table below shows the annual total liabilities of Ningbo MedicalSystem Biotechnology Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥771.65 Million ≈ $112.92 Million |
-1.39% |
| 2023-12-31 | CN¥782.49 Million ≈ $114.50 Million |
-26.47% |
| 2022-12-31 | CN¥1.06 Billion ≈ $155.73 Million |
-11.49% |
| 2021-12-31 | CN¥1.20 Billion ≈ $175.96 Million |
-23.27% |
| 2020-12-31 | CN¥1.57 Billion ≈ $229.33 Million |
-33.38% |
| 2019-12-31 | CN¥2.35 Billion ≈ $344.25 Million |
+1.09% |
| 2018-12-31 | CN¥2.33 Billion ≈ $340.54 Million |
+16.84% |
| 2017-12-31 | CN¥1.99 Billion ≈ $291.46 Million |
+25.27% |
| 2016-12-31 | CN¥1.59 Billion ≈ $232.66 Million |
+897.74% |
| 2015-12-31 | CN¥159.36 Million ≈ $23.32 Million |
-22.69% |
| 2014-12-31 | CN¥206.12 Million ≈ $30.16 Million |
+26.77% |
| 2013-12-31 | CN¥162.59 Million ≈ $23.79 Million |
+26.38% |
| 2012-12-31 | CN¥128.66 Million ≈ $18.83 Million |
+88.31% |
| 2011-12-31 | CN¥68.32 Million ≈ $10.00 Million |
-- |
About Ningbo MedicalSystem Biotechnology Co Ltd
Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products in China. It is also involved in the provision of Three-party medical diagnosis services. The company offers automated chemistry analyzers; and automated chemiluminescence immunoassay analyzer; hematology analyzers and reagents; total laboratory automation system; mass… Read more